The latest developments on Ebola, hepatitis B, long Covid

By
Theresa Gaffney
May 28, 2026
0 min

Stat News

Overview

Recent findings highlight the closure of Uganda's border amid an Ebola outbreak, the prevalence of long COVID in 1 in 6 COVID-19 patients, and promising results from a hepatitis B treatment trial.

Background

Ebola virus disease remains a critical public health concern, particularly with the emergence of new outbreaks. Long COVID presents significant long-term health implications for a substantial portion of COVID-19 survivors. Additionally, chronic hepatitis B infections pose a global health challenge.

Data Highlights

No specific numerical data available in the source material.

Key Findings

Uganda has closed its border with the Democratic Republic of Congo due to an Ebola outbreak, contrary to WHO guidance.
Approximately 1 in 6 patients with COVID-19 develop long COVID, a rate higher than previously estimated.
In clinical trials, an experimental GSK drug achieved a functional cure in about 20% of hepatitis B patients.
Chronic hepatitis B infections can lead to severe complications, including cirrhosis and liver cancer.

Clinical Implications

Health professionals should remain vigilant regarding the management of Ebola outbreaks and the implications of long COVID on patient care. The advancements in hepatitis B treatment may provide new options for patients, though further research is necessary.

Conclusion

The ongoing research and developments in the management of Ebola, hepatitis B, and long COVID highlight the complexities of infectious diseases and the need for continued innovation in treatment and public health strategies.